文献速递肿瘤 PET/CT

18F-FDG PET/CT在预测非贲门胃癌术前化疗后肿瘤消退中的有限价值:意大利胃癌研究组(GIRCG)经验

Limited Usefulness of 18F-FDG PET/CT in Predicting Tumor Regression After Preoperative Chemotherapy for Noncardia Gastric Cancer: The Italian Research Group for Gastric Cancer (GIRCG) Experience.
PubMed 文献 · Clin Nucl Med · 2020-01-01

本研究纳入6个意大利中心的71例接受术前化疗的非贲门胃癌患者,于基线和治疗后测量18F-FDG PET/CT的SUV并计算差值(dSUV),评估PET指标与Becker评分定义的病理肿瘤消退(PTR)及生存的关系。dSUV绝对值(ROC-AUC 0.73;95%CI 0.59-0.87)或百分比(ROC-AUC 0.74;95%CI 0.59-0.89)仅能部分区分有无PTR,仅极端值有信息价值。作者认为18F-FDG PET/CT预测肿瘤消退的价值有限。

要点

  • dSUV百分比ROC-AUC为0.74(95%CI 0.59-0.89),绝对值ROC-AUC为0.73(95%CI 0.59-0.87)。
  • 7例FDG摄取较基线增加者病理检查均无肿瘤消退。
  • 代谢反应≥70%的10例中7例达Becker 1a或1b;0%-70%的54例无法可靠预测消退。

核心结论

  • 本研究提示18F-FDG PET/CT在预测胃癌消退方面价值有限。
  • 系列测量中缺乏代谢反应提示术前治疗可能无效。

研究设计与样本

  • 研究纳入6个意大利中心的71例接受术前化疗的非贲门胃癌患者。
  • 于基线和治疗后测量18F-FDG PET/CT的SUV并计算差值(dSUV)。
  • 以Becker评分评估病理肿瘤消退(PTR),用非参数回归分析PET指标与PTR的关联。
  • 用ROC曲线及曲线下面积(ROC-AUC)评价PET指标判别PTR缺失(Becker 2/3)的能力。

主要发现

  • dSUV绝对值可部分区分有无PTR,ROC-AUC为0.73(95%CI 0.59-0.87)。
  • dSUV百分比可部分区分有无PTR,ROC-AUC为0.74(95%CI 0.59-0.89)。
  • 仅dSUV百分比的极端值真正具有信息价值。
  • 7例FDG摄取较术前治疗增加者病理检查均无肿瘤消退。
  • 代谢反应≥70%的10例中7例达Becker评分1a或1b(完全或近完全病理消退)。

关键数值与推荐

  • PTR采用Becker评分评估,PTR缺失定义为Becker 2/3。
  • dSUV绝对值判别PTR缺失的ROC-AUC为0.73(95%CI 0.59-0.87)。
  • dSUV百分比判别PTR缺失的ROC-AUC为0.74(95%CI 0.59-0.89)。
  • 代谢反应≥70%的10例中7例达Becker 1a或1b。
  • 代谢反应0%-70%的54例无法可靠预测病理肿瘤消退。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present study aimed to better define the usefulness of F-FDG PET/CT in predicting pathological tumor response (PTR) and survival in patients with noncardia gastric cancer treated with preoperative chemotherapy. METHODS: Seventy-one patients were recruited in 6 Italian centers. The SUV of F-FDG PET/CT was measured at baseline and after treatment, and the difference (dSUV) was computed. The association between PET indexes and PTR, assessed by the Becker score, was evaluated by nonparametric regression. The discriminant power of PET indexes with respect to the absence of PTR (Becker 2/3) was studied by receiver operating characteristic (ROC) curve and synthesized by the area under the curve (ROC-AUC). RESULTS: dSUV allowed to partially discriminate between absence/presence of PTR, when expressed as either absolute value (ROC-AUC, 0.73; 95% confidence interval, 0.59-0.87) or percentage (ROC-AUC, 0.74; 95% confidence interval, 0.59-0.89). However, only extreme values of percent dSUV were really informative. All 7 patients whose F-FDG uptake had increased despite preoperative treatment showed no tumor regression at pathologic examination. Seven of the 10 patients whose metabolic response had been 70% or greater had complete or nearly complete pathologic tumor regression (Becker score 1a or 1b). The metabolic response of the remaining 54 patients, which ranged between 0% and 70%, did not permit to reliably forecast pathologic tumor regression. Survival significantly decreased with increasing Becker score but was unaffected by metabolic response. CONCLUSIONS: The present study suggests that F-FDG PET/CT has limited usefulness in predicting cancer regression. The lack of metabolic response in serial measurements indicates the probable ineffectiveness of preoperative treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Morgagni P, Bencivenga M, Colciago E, et al. Limited Usefulness of 18F-FDG PET/CT in Predicting Tumor Regression After Preoperative Chemotherapy for Noncardia Gastric Cancer: The Italian Research Group for Gastric Cancer (GIRCG) Experience. Clin Nucl Med. 2020. PMID: 31977470. doi:10.1097/RLU.0000000000002911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。